Disc Medicine, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Disc Medicine, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-12-31 was 116.88K shares, a 47.49% increase year-over-year.
- Disc Medicine, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-09-30 was 34.81K shares, a 40.96% decline year-over-year.
- Disc Medicine, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-06-30 was 68.11K shares, a 64.22% increase year-over-year.
- Disc Medicine, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-03-31 was 95.47K shares, a 27.71% increase year-over-year.
- Disc Medicine, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 578.87K shares, a 83.61% increase from fiscal 2024.
- Disc Medicine, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 315.27K shares, a 23.91% increase from fiscal 2023.
- Disc Medicine, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 254.43K shares, a 378.04% increase from fiscal 2022.
- Disc Medicine, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 53.22K shares, a 74.52% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2025-12-31 | 578.87K shares 10-K · filed 2026-02-26 | |
| 2024-12-31 | 116.88K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 315.27K shares 10-K · filed 2025-02-27 |
| 2024-09-30 | 34.81K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 277.63K shares derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | 68.11K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 301.78K shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 95.47K shares 10-Q · filed 2024-05-09 | 275.15K shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 79.24K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | 254.43K shares 10-K · filed 2024-03-21 |
| 2023-09-30 | 58.96K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | |
| 2023-06-30 | 41.48K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | |
| 2023-03-31 | 74.75K shares 10-Q · filed 2023-05-15 | |
| 2022-12-31 | 53.22K shares 10-K · filed 2023-03-31 | |
| 2021-12-31 | 208.89K shares 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |